Castle Biosciences to Present at Baird Global Healthcare Conference on Sept. 10.
PorAinvest
jueves, 21 de agosto de 2025, 7:03 am ET1 min de lectura
CSTL--
Additionally, Castle Biosciences' executive management will be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on September 11, 2025. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets [1].
Castle Biosciences aims to transform disease management by providing innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett’s esophagus, and uveal melanoma. They also have active research and development programs for tests in these and other diseases with high clinical need [1].
Recently, Derek J. Maetzold, President & Chief Executive Officer and Director at Castle Biosciences, sold 43,019 shares of Common Stock on August 13, 2025, at a weighted average price of $19.504 per share, totaling $839,042. Following the transaction, Maetzold directly owns 69,683 shares and indirectly owns 261,372 shares through various trusts [2].
References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html
[2] https://www.tradingview.com/news/tradingview:2cf6a17818acc:0-castle-biosciences-ceo-derek-j-maetzold-sells-shares/
Castle Biosciences announced that its executive management will present a company overview at Baird's 2025 Global Healthcare Conference on Sept. 10, 2025. The presentation will be live-streamed on the company's website. The executive team will also be available for one-on-one investor meetings during the Wells Fargo and Lake Street Capital Markets conferences on Sept. 4 and Sept. 11, respectively.
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, has announced its participation in several upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10, 2025, at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website [1].Additionally, Castle Biosciences' executive management will be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on September 11, 2025. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets [1].
Castle Biosciences aims to transform disease management by providing innovative tests that guide patient care. The company's current portfolio includes tests for skin cancers, Barrett’s esophagus, and uveal melanoma. They also have active research and development programs for tests in these and other diseases with high clinical need [1].
Recently, Derek J. Maetzold, President & Chief Executive Officer and Director at Castle Biosciences, sold 43,019 shares of Common Stock on August 13, 2025, at a weighted average price of $19.504 per share, totaling $839,042. Following the transaction, Maetzold directly owns 69,683 shares and indirectly owns 261,372 shares through various trusts [2].
References:
[1] https://www.stocktitan.net/news/CSTL/castle-biosciences-to-participate-in-upcoming-investor-g51lxflqidnb.html
[2] https://www.tradingview.com/news/tradingview:2cf6a17818acc:0-castle-biosciences-ceo-derek-j-maetzold-sells-shares/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios